Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 102-109

  Tabbekh, Mouna ^a   Franciszkiewicz, Katarzyna ^a   Haouas, Houda ^b   Lécluse, Yann ^c   Benihoud, Karim ^c   Raman, Chander ^d   Mami Chouaib, Fathia ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF CARTHAGE   (Tunisia)

^c CNRS   (France)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INFILTRATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOMODULATION; KNOCKOUT MOUSE; LEUKOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ENGRAFTMENT; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WILD TYPE;

ANIMALS; ANTIGENS, CD5; CARCINOMA, LEWIS LUNG; CELL DEATH; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 79960434337     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004145     Document Type: Article

References (42)

1. Kodama, T., M. Freeman, L. Rohrer, J. Zabrecky, P. Matsudaira, and M. Krieger. 1990. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343: 531-535.
2. Resnick, D., A. Pearson, and M. Krieger. 1994. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem. Sci. 19: 5-8.
3. Jones, N. H., M. L. Clabby, D. P. Dialynas, H. J. Huang, L. A. Herzenberg, and J. L. Strominger. 1986. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature 323: 346-349.
4. Beyers, A. D., L. L. Spruyt, and A. F. Williams. 1992. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc. Natl. Acad. Sci. USA 89: 2945-2949.
5. Tarakhovsky, A., S. B. Kanner, J. Hombach, J. A. Ledbetter, W. Müller, N. Killeen, and K. Rajewsky. 1995. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269: 535-537.
6. Peña-Rossi, C., L. A. Zuckerman, J. Strong, J. Kwan, W. Ferris, S. Chan, A. Tarakhovsky, A. D. Beyers, and N. Killeen. 1999. Negative regulation of CD4 lineage development and responses by CD5. J. Immunol. 163: 6494-6501.
7. Gimferrer, I., M. Farnós, M. Calvo, M. Mittelbrunn, C. Enrich, F. Sánchez-Madrid, J. Vives, and F. Lozano. 2003. The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J. Biol. Chem. 278: 8564-8571.
8. Brossard, C., M. Semichon, A. Trautmann, and G. Bismuth. 2003. CD5 inhibits signaling at the immunological synapse without impairing its formation. J. Immunol. 170: 4623-4629. (Pubitemid 36519968)
9. Bhandoola, A., R. Bosselut, Q. Yu, M. L. Cowan, L. Feigenbaum, P. E. Love, and A. Singer. 2002. CD5-mediated inhibition of TCR signaling during intra-thymic selection and development does not require the CD5 extracellular domain. Eur. J. Immunol. 32: 1811-1817.
10. Gary-Gouy, H., J. Harriague, A. Dalloul, E. Donnadieu, and G. Bismuth. 2002. CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J. Immunol. 168: 232-239. (Pubitemid 34014123)
11. Biancone, L., M. A. Bowen, A. Lim, A. Aruffo, G. Andres, and I. Stamenkovic. 1996. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J. Exp. Med. 184: 811-819.
12. Bikah, G., F. M. Lynd, A. A. Aruffo, J. A. Ledbetter, and S. Bondada. 1998. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. Int. Immunol. 10: 1185-1196.
13. Calvo, J., L. Places, O. Padilla, J. M. Vilà, J. Vives, M. A. Bowen, and F. Lozano. 1999. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand. Eur. J. Immunol. 29: 2119-2129.
14. Van de Velde, H., I. von Hoegen, W. Luo, J. R. Parnes, and K. Thielemans. 1991. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 351: 662-665. (Pubitemid 21896665)
15. Brown, M. H., and E. Lacey. 2010. A ligand for CD5 is CD5. J. Immunol. 185: 6068-6074.
16. Vera, J., R. Fenutría, O. Cañadas, M. Figueras, R. Mota, M. R. Sarrias, D. L. Williams, C. Casals, J. Yelamos, and F. Lozano. 2009. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc. Natl. Acad. Sci. USA 106: 1506-1511.
17. Berland, R., S. Fiering, and H. H. Wortis. 2010. A conserved enhancer element differentially regulates developmental expression of CD5 in B and T cells. J. Immunol. 185: 7537-7543.
18. Arman, M., J. Calvo, M. E. Trojanowska, P. N. Cockerill, M. Santana, M. López-Cabrera, J. Vives, and F. Lozano. 2004. Transcriptional regulation of human CD5: important role of Ets transcription factors in CD5 expression in T cells. J. Immunol. 172: 7519-7529. (Pubitemid 38747615)
19. Azzam, H. S., A. Grinberg, K. Lui, H. Shen, E. W. Shores, and P. E. Love. 1998. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J. Exp. Med. 188: 2301-2311.
20. Dorothée, G., I. Vergnon, F. El Hage, B. Le Maux Chansac, V. Ferrand, Y. Lécluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib. 2005. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J. Immunol. 174: 6888-6897.
21. Hawiger, D., R. F. Masilamani, E. Bettelli, V. K. Kuchroo, and M. C. Nussenzweig. 2004. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695-705.
22. Stamou, P., J. de Jersey, D. Carmignac, C. Mamalaki, D. Kioussis, and B. Stockinger. 2003. Chronic exposure to low levels of antigen in the periphery causes reversible functional impairment correlating with changes in CD5 levels in monoclonal CD8 T cells. J. Immunol. 171: 1278-1284. (Pubitemid 36900058)
23. Kassiotis, G., R. Zamoyska, and B. Stockinger. 2003. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J. Exp. Med. 197: 1007-1016.
24. Axtell, R. C., L. Xu, S. R. Barnum, and C. Raman. 2006. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17- expressing T cells in the central nervous system. J. Immunol. 177: 8542-8549. (Pubitemid 44893816)
25. Budd, R. C. 2001. Activation-induced cell death. Curr. Opin. Immunol. 13: 356-362.
26. Axtell, R. C., M. S. Webb, S. R. Barnum, and C. Raman. 2004. Cutting edge: critical role for CD5 in experimental autoimmune encephalomyelitis: inhibition of engagement reverses disease in mice. J. Immunol. 173: 2928-2932. (Pubitemid 39141996)
27. Friedlein, G., F. El Hage, I. Vergnon, C. Richon, P. Saulnier, Y. Lécluse, A. Caignard, L. Boumsell, G. Bismuth, S. Chouaib, and F. Mami-Chouaib. 2007. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J. Immunol. 178: 6821-6827. (Pubitemid 46847407)
28. Hiraoka, K., S. Yamamoto, S. Otsuru, S. Nakai, K. Tamai, R. Morishita, T. Ogihara, and Y. Kaneda. 2004. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173: 4297-4307. (Pubitemid 39280657)
29. Descamps, D., F. Vigant, S. Esselin, E. Connault, P. Opolon, M. Perricaudet, and K. Benihoud. 2006. Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis. Hepatology 44: 399-409. (Pubitemid 44214879)
30. Dorothée, G., I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib. 2002. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J. Immunol. 169: 809-817. (Pubitemid 34753437)
31. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
32. Dasu, T., J. E. Qualls, H. Tuna, C. Raman, D. A. Cohen, and S. Bondada. 2008. CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol. Lett. 119: 103-113.
33. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17: 221-253.
34. Tarakhovsky, A., W. Müller, and K. Rajewsky. 1994. Lymphocyte populations and immune responses in CD5-deficient mice. Eur. J. Immunol. 24: 1678-1684.
35. Jameson, S. C., K. A. Hogquist, and M. J. Bevan. 1995. Positive selection of thymocytes. Annu. Rev. Immunol. 13: 93-126.
36. Azzam, H. S., J. B. DeJarnette, K. Huang, R. Emmons, C. S. Park, C. L. Sommers, D. El-Khoury, E. W. Shores, and P. E. Love. 2001. Fine tuning of TCR signaling by CD5. J. Immunol. 166: 5464-5472.
37. Ryan, K. R., D. McCue, and S. M. Anderton. 2005. Fas-mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation. J. Leukoc. Biol. 78: 43-50.
38. Sun, T., Y. Zhou, H. Li, X. Han, Y. Shi, L. Wang, X. Miao, W. Tan, D. Zhao, X. Zhang, et al. 2005. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med. 202: 967-974.
39. Norell, H., T. Martins da Palma, A. Lesher, N. Kaur, M. Mehrotra, O. S. Naga, N. Spivey, S. Olafimihan, N. G. Chakraborty, C. Voelkel-Johnson, et al. 2009. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res. 69: 6282-6289.
40. Zaks, T. Z., D. B. Chappell, S. A. Rosenberg, and N. P. Restifo. 1999. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162: 3273-3279.
41. Huang, J., H. T. Khong, M. E. Dudley, M. El-Gamil, Y. F. Li, S. A. Rosenberg, and P. F. Robbins. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28: 258-267.
42. Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell, Jr., and S. A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173: 7125-7130.